Past
May 1–4, 2025 – Portland, OR
American Nephrology Nurses Association (ANNA) National Symposium 2025
The Dual Impact of Sparsentan on Inflammation and Proteinuria in IgA Nephropathy
Travere and GlomCon
The Dual Impact of Sparsentan on Inflammation and Proteinuria in IgA Nephropathy
Participants
Moderator: Dia Waguespack, MD, UTHealth, Houston, TX
Speaker: Chris Gisler, MD, Travere Therapeutics, Inc., Senior Medical Director
Panelists:
- Raymond Hsu, MD, MAS, UCSF Health, San Francisco, CA
- Zainab Obaidi, MD, University of Chicago, Chicago, IL
Objectives
In this webinar we:
- Reviewed the indication and mode of action (MoA) of sparsentan in IgA nephropathy, including recent updates to the Risk Evaluation and Mitigation Strategies (REMS) requirements
- Highlighted the efficacy and safety findings from the Phase 3 PROTECT trial, including results from a post hoc analysis of proteinuria remission
- Discussed the potential effects of sparsentan on kidney-specific inflammation and glomerular health, as assessed in animal models
- Explored efficacy, safety, and potential anti-inflammatory effects of sparsentan from the Phase 2 SPARTAN Study
- Examined the efficacy and safety of replacing renin-angiotensin system inhibitors (RASi) with sparsentan in patients concurrently on sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Browse our collection of related resources
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients With IgA Nephropathy (PROTECT): 2-year Results From a Randomised, Active-Controlled, Phase 3 Trial
Authors: Rovin BH, Barratt J, Heerspink HJL et al.
Type: Publication
Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
Authors: Heerspink JLH, Tesar V, Komers R et al.
Type: Poster
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial
Authors: Cheung CK, Moody S, Dhaun N et al.
Type: Presentation
Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti-inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study
Authors: Cheung CK, Barratt WA, Chaki S et al.
Type: Presentation
Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
Authors: Ayoub I, Tang S, Kooienga L et al.
Type: Presentation
Sparsentan Is Superior to Losartan in the gddY Mouse Model of IgA Nephropathy
Authors: Nagasawa H, Ueda S, Suzuki H et al.
Type: Publication
